The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer
Open accessAbstract
Replicative immortality is a hallmark of cancer cells governed by telomere maintenance. Approximately 90% of human cancers maintain their telomeres by activating telomerase, driven by the transcriptional upregulation of telomerase reverse transcriptase (TERT). Although TERT promoter mutations (TPMs) are a major cancer-associated genetic mechanism of TERT upregulation, many cancers exhibit TERT upregulation without TPMs. In this study, we describe the TERT hypermethylated oncological region (THOR), a 433-bp genomic region encompassing 52 CpG sites located immediately upstream of the TERT core promoter, as a cancer-associated epigenetic mechanism of TERT upregulation. Unmethylated THOR repressed TERT promoter activity regardless of TPM status, and hypermethylation of THOR counteracted this repressive function. THOR methylation analysis in 1,352 human tumors revealed frequent (>45%) cancer-associated DNA hypermethylation in 9 of 11 (82%) tumor types screened. Additionally, THOR hypermethylation, either independently or along with TPMs, accounted for how approximately 90% of human cancers can aberrantly activate telomerase. Thus, we propose that THOR hypermethylation is a prevalent telomerase-activating mechanism in cancer that can act independently of or in conjunction with TPMs, further supporting the utility of THOR hypermethylation as a prognostic biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
The common biology of cancer and ageing
Finkel, T., Serrano, M., & Blasco, M. A. (2007) · Nature · doi:10.1038/nature05985 · Cited by 988
TERT promoter mutations and telomerase reactivation in urothelial cancer
Borah, S., Xi, L., Zaug, A. J., Powell, N. M., Dancik, G. M., Cohen, S. B., Costello, J. C., Theodorescu, D., & Cech, T. R. (2015) · Science · doi:10.1126/science.1260200 · Cited by 292
Guilleret, I., Yan, P., Grange, F., Braunschweig, R., Bosman, F. T., & Benhattar, J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10593 · Cited by 260 · cited 1×
“Previous seminal studies have reported an association between TERT promoter hypermethylation and elevated TERT expression in cancer (17, 18), leading to our recent work, which uncovered this association in a specific region within the TERT promoter, termed upstream of the Replicative immortality is a hallmark of cance…”
Zinn, R. L., Pruitt, K., Eguchi, S., Baylin, S. B., & Herman, J. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3396 · Cited by 210
Cited by
Yuan, X., Larsson, C., & Xu, D. (2019) · Oncogene · doi:10.1038/s41388-019-0872-9 · Cited by 450
TERT—Regulation and Roles in Cancer Formation
Dratwa, M., Wysoczańska, B., Łacina, P., Kubik, T., & Bogunia-Kubik, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589929 · Cited by 311
Telomeres and Telomere Length: A General Overview
Srinivas, N., Rachakonda, S., & Kumar, R. (2020) · Cancers · doi:10.3390/cancers12030558 · Cited by 304
Promoter DNA Hypermethylation and Paradoxical Gene Activation
Smith, J., Sen, S., Weeks, R. J., Eccles, M. R., & Chatterjee, A. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.007 · Cited by 274
Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer
Chen, X., Zhang, J., Ruan, W., Huang, M., Wang, C., Wang, H., Jiang, Z., Wang, S., Liu, Z., Liu, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139597 · Cited by 259
Metadata
- Authors
- Lee, D. D., Leão, R., Komosa, M., Gallo, M., Zhang, C. H., Lipman, T., Remke, M., Heidari, A., Nunes, N. M., Apolónio, J. D., Price, A. J., De Mello, R. A., Dias, J. S., Huntsman, D., Hermanns, T., Wild, P. J., Vanner, R., Zadeh, G., Karamchandani, J., Das, S., Taylor, M. D., Hawkins, C. E., Wasserman, J. D., Figueiredo, A., Hamilton, R. J., Minden, M. D., Wani, K., Diplas, B., Yan, H., Aldape, K., Akbari, M. R., Danesh, A., Pugh, T. J., Dirks, P. B., Castelo-Branco, P., & Tabori, U.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-12-03
- Volume
- 129
- Issue
- 1
- Pages
- 223-229
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2898125316
- Cited by
- 183
- References
- 5
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.